Neuromuscular Disorders
Conference Coverage
Carpal tunnel syndrome may flag cardiac amyloidosis in elderly
DALLAS – Tenosynovial amyloidosis signaled cardiac involvement in some patients undergoing carpal tunnel release surgery.
Patient Information
Tips for Living With Ataxia
People with ataxia lose muscle control in their legs and arms, which can lead to a lack of coordination and balance, as well as gait disturbance....
From the Journals
Painful autoimmune neuropathy may mimic Guillain-Barré syndrome
Be on the lookout for acute transient immune responses against small nerve fibers in patients suspected of having Guillain-Barré syndrome.
From the Journals
New trial shows thymectomy benefits myasthenia gravis
New trial moves toward settling thymectomy debate for myasthenia gravis.
Latest News
Course and outcome of Guillain-Barré syndrome measured in ongoing study
More than 1,500 patients have been enrolled so far.
Conference Coverage
Gene therapy for spinal muscular atrophy shows promise in early study
BOSTON – Early data show remarkable results for a gene therapy with few adverse events, in a phase I study.
Conference Coverage
Nusinersen for early spinal muscular atrophy: Final findings beat interim results
BOSTON – But the drug costs $750,000 a year, and questions remain about its use.
Conference Coverage
PATH study: Subcutaneous immunoglobulin safe, effective for CIDP maintenance
BOSTON – No differences in relapse recurrence were noted between low and high doses in the randomized, placebo-controlled, phase III study.
News
FDA approves first new drug for ALS in decades
Edaravone (Radicava) is only the second drug ever to be approved by the agency for amyotrophic lateral sclerosis.
Conference Coverage
VIDEO: About 1 in 20 ALS patients in Washington state chose assisted suicide
BOSTON – ALS patients were more likely to take deadly meds postprescription than were cancer patients.
Conference Coverage
VIDEO: Big research trials at AAN bring up important cost decisions
BOSTON – How will neurologists strike a balance between new drugs’ improved efficacy and safety and their affordability for patients?